Relocation assistance is available for qualified candidates.
Labcorp provides end-to-end R&D services for life sciences and agricultural clients, including crop protection, with testing and regulatory support. It runs physicochemical analyses, safety assessments, and inhalation toxicology studies using specialized labs to evaluate inhaled substances. It differentiates itself with a global footprint and an integrated set of services across the product lifecycle, including regulatory submissions. Its goal is to help clients bring safe, effective products to market efficiently by applying rigorous science and scalable testing.
Company Size
10,001+
Company Stage
IPO
Headquarters
Burlington, Vermont
Founded
1976
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
Unlimited Paid Time Off
Tuition Reimbursement
Employee Stock Purchase Plan
Labcorp Holdings stock fell 3.3% on Tuesday after the Centers for Medicare & Medicaid Services announced it will cut reimbursement rates for lab work by up to 15%, effective 1 January 2027. CMS disclosed it has been paying approximately 16% more for lab work than private insurers. The agency estimates the reduced rates will save taxpayers $1 billion annually. Labcorp derives roughly 8% of its revenue from CMS reimbursement, meaning a full 15% rate reduction would decrease annual revenue by 1.2%. Successive 15% yearly reductions are possible through 2029, implying a worst-case scenario of approximately 3.6% revenue reduction. In its latest SEC filing, Labcorp identified Medicare and Medicaid rate reductions as a key investment risk.
Teal Health has raised $22 million in Series A funding, taking its total funding to $45 million as it prepares to expand access to at-home HPV cervical cancer screening.
Evvy has raised $40 million in an oversubscribed Series B round led by Catalio Capital to expand its vaginal microbiome platform into reproductive healthcare, focusing on fertility and IVF. The round included U.S. Fertility's Innovation Fund, Labcorp Venture Fund, and existing investors including General Catalyst and Left Lane Capital, bringing total funding to nearly $60 million. The company has served over 100,000 patients and partnered with 3,000 healthcare practitioners, building what it describes as the world's largest proprietary dataset on the vaginal microbiome. Ninety-six percent of patients contribute data anonymously to clinical research. Evvy's at-home Vaginal Health Test analyses over 700 bacteria and fungi using metagenomic sequencing, priced at $159 per test. The funding will scale EvvyAI, the company's data and AI platform underlying its diagnostic services. CEO Priyanka Jain aims to make vaginal microbiome screening routine preventive care, comparable to Pap smears, addressing areas where women's health research has historically been limited.
Evvy, a female-founded startup unlocking precision women’s healthcare through biomarker discovery, announced today the closing of a $14 million Series A fund...
Labcorp hosted its 2026 Investor Day on 10 September, outlining its growth strategy and long-term financial outlook through 2029. The company expects compound annual revenue growth of 5% to 8% and adjusted earnings per share growth of 8.5% to 11.5% through 2029. Chairman and CEO Adam Schechter said Labcorp is positioned at the intersection of diagnostics, biopharma, science and technology. The company reaffirmed its 2026 guidance, projecting enterprise revenue growth of 5.4% to 6.3%. Labcorp's Diagnostics Laboratories division is expected to grow 5.3% to 6.0%, whilst Biopharma Laboratory Services is forecast to grow 5.5% to 6.5%. Chief Financial Officer Julia Wang cited the company's proven delivery record and disciplined value creation framework as underpinning this outlook. The company employs nearly 71,000 people and serves clients in approximately 100 countries.